Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 14498	/PTO	Complete if Known		
O I P ANFORMATIO	ON DISCLO	SURE	Application Number	09/835/298	
STATEMENT			Filing Date	4/13/01	
OCT 2 3\			First Named Inventor	Dahlen et al.	
OCT 3 0 2006 8	•		Group Art Unit	1641	
(use as many sheets as necessary)		Examiner Name	Ann Y. Lam		
speet	of	3	Attorney Docket Number	071949-5301	

U.S. PATENT DOCUMENTS							
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	A1	6756483		Bergmann et al.	06-29-2004		

			U.S	. PATENT APPLICATION DOCUM	MENTS	· .	
Examiner Initials*	Cito	U.S. Patent Application Document		Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant	
	Cite No. ¹	Serial Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
			-				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸		
Ü	A2	WO 00/22439	B.R.A.H.M.S. Diagnostica GMBH	04-20-2000				

		NON PATENT LITERATURE DOCUMENTS	
Exami ner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
QC	A3	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Section 2.3, p. e8.	
Ü	A4	ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction, "Overview of Acute Coronary Syndrome," pages 4 and 20.	

Examiner Signature	In Kan	Date Considered	1/19/07

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 2Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	or form 1449B	/PTO	•		
INFORMATION DISCLOSURE				Application Number	09/835/298	
	STATEMENT BY APPLICANT			Filing Date	4/13/01	
				First Named Inventor	Dahlen et al.	
				Group Art Unit	1641	
(use as many sheets as necessary)			cessary)	Examiner Name	Ann Y. Lam	
Sheet	2	of	3	Attorney Docket Number	071949-5301	

		NON PATENT LITERATURE DOCUMENTS	
Exami ner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Q	A5	American College of Cardiology and the Joint European Society of Cardiology, J. Am. Coll. Cardiol. 36: 959-969 (2000), Albert et al., section entitled "II. Clinical Presentation," p. 960.	
U	A6	Goetze et al., "Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing," Clin. Chem. 48: 1035-42, 2002	
Œ	A7	HASSAN et al., "Non-viable myocardium, documented by TL-201 SPECT, is a main determinant of the increase in the secretion of cardiac natriuretic peptides" Medecine Nucleaire, 2000, 24/6, pp 301-310 (Database EMBASE Accession No. 2001129199 and English language translation)	
Œ	A8	Omland et al., N-terminal Pro-B-Type natriuretic peptide and long-term mortality in acute coronary syndrome. Circulation 106: 2913-18 (2002)	
AP	A9	Rabbani, Editorials, "Acute coronary syndromes-Beyond Myocyte necrosis." N. Engl. J. Med. 345: 1057-59 (2001)	
Ř	A10	Sagnella, "Measurement and importance of plasma brain natriuretic peptide and related peptides," Ann. Clin. Biochem. 38: 83-93, 2001	
æ	A11	Shimizu et al., "Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system," Clin. Chim. Acta 305: 181-6, 2001	

Examiner Signature	Callen	Date Considered	1/19/07

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	or form 1449B	/PTO	Complete if Known		
	INFORMATI	ON DISCLO	SURE	Application Number	09/835/298	
	STATEMENT BY APPLICANT			Filing Date	4/13/01	
				First Named Inventor	Dahlen et al.	
				Group Art Unit	1641	
(use as many sheets as necessary)				Examiner Name	Ann Y. Lam	
Sheet	3	of	3	Attorney Docket Number	071949-5301	

NON PATENT LITERATURE DOCUMENTS							
Exami ner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ*				
Qe	A12	Silver et al., "BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Disease," CHF 10[5 Suppl. 3]: 1-30 (2004)					

Examiner Signature	Ga / Lan	Date Considered	1/19/07.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language